Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CK-3762601
- Development stage
- Preclinical
- Lead developer
- Cytokinetics
- Modality
- Small Molecules
01
Overview
CK-3762601 is a next-generation fast skeletal muscle troponin activator (FSTA) small molecule developed for conditions of muscle weakness. It directly targets fast skeletal troponin C, increasing the calcium sensitivity of the actin filament in fast-twitch myofibers, thereby enhancing contractile force in skeletal muscle. Its preclinical development has been focused on improving muscle performance and treating diseases characterized by skeletal muscle dysfunction, such as ICU-acquired diaphragm weakness and other conditions involving impaired muscle strength[1][3][4][5][6][7][11][13].
- Brand names
- ck-601ck601ck 601
- Other names
- ck-601ck601ck 601
02
Targets
fsTroponin complex (Fast skeletal muscle troponin complex)
Beyond the preview
Go deeper on CK-3762601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CK-3762601.